Compare Becton Dickinson and Co (BDX) vs CAVA Group Inc (CAVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs CAVA Group Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while CAVA Group Inc trades at $71.58 (market cap $8.15B). The key difference: Becton Dickinson and Co is far larger — about 5.1× CAVA Group Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while CAVA Group Inc pays none. Which is the better fit depends on your goals.
| BDX | CAVA | |
|---|---|---|
Market Cap | $41.51B | $8.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $97.39 |
52-Week Low | $135.49 | $43.59 |
Enterprise Value | $57.97B | $8.25B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
CAVA trades at $72.54, up 0.5% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong revenue growth and expansion momentum, but faces high valuation multiples and margin pressures. Recent news highlights aggressive store openings and technology investments driving traffic, though the stock has experienced volatility amid market fluctuations.
Outlook remains growth-focused with analyst consensus bullish, targeting $94.73, but risks include elevated P/E of 134.56, competitive pressures, and potential margin compression from expansion costs. The stock offers upside if execution continues, but requires careful monitoring of profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About CAVA Group Inc
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →
